The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease

Endocrine Reviews

Volumn 19, Issue 5, 1998, Pages 583-592

  Haffner, Steven M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEFICIENCY; INSULIN RESISTANCE; INSULIN SYNTHESIS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PATIENT SCHEDULING; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0031665831     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.19.5.0343     Document Type: Review

References (109)

1. Sharrett AR, Chambless LE, Heiss G, Paton CC, Patsch W for the ARIC Investigators 1995 Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 15:2122-2129
2. Ginsberg HN, Jones J, Blaner WS, Thomas A, Karmally W, Fields L, Blood D, Begg MD 1995 Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol 15:1829-1838
3. Kannel WB, McGee DL 1979 Diabetes and cardiovascular disease. The Framingham Study. JAMA 241:2035-2038
4. Wingard DL, Barrett-Connor E 1995 Heart disease and diabetes. In: Diabetes in America, 2nd ed. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Diabetes Data Group, pp 429-448
5. Stamler J, Vaccaro O, Neaton JD, Wentworth D 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434-444
6. Jarrett RJ, Shipley MJ 1988 Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease-putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia 31:737-740
7. Herman JB, Medalie JH, Goldbourt U 1977 Differences in cardiovascular morbidity and mortality between previously known and newly diagnosed adult diabetics. Diabetologia 13:229-234
8. Jarrett RJ 1984 Type 2 (non-insulin-dependent) diabetes mellitus and coronary heart disease-chicken, egg or neither? Diabetologia 26:99-102
9. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK 1990 Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heat disease start ticking before the onset of clinical diabetes? JAMA 263:2893-2898
10. Klein R 1995 Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18:258-268
11. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hörmann A, Holle R 1996 Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39:1540-1545
12. Lehto S, Ronnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M 1997 Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354-1359
13. Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, Schwanebeck U, Julius U 1991 Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 14:308-317
14. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J, the DIS Group 1996 Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583
15. Wingard DL, Barrett-Connor E 1987 Family history of diabetes and cardiovascular disease risk factors and mortality among euglycemic, borderline hyperglycemic, and diabetic adults. Am J Epidemiol 125:948-958
16. Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving H-H 1995 Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44:1303-1309
17. Laakso M, Lehto S, Penttila I, Pyörälä K 1993 Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 88:1421-1430
18. Andersson DK, Svardsudd K 1995 Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 18:1534-1543
19. Moss SE, Klein R, Klein BE, Meuer SM 1994 The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 154:2473-2479
20. Pan XR, Hu YH, Li GW, Liu PA, Bennett PH, Howard BV 1993 Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and diabetes study. Diabetes Care 16:150-156
21. Ohlson LO, Bjuro T, Larsson B, Eriksson H, Svardsudd K, Welin L, Wilhelmsen L 1989 A cross-sectional analysis of glucose tolerance and cardiovascular disease in 67-year-old men. Diabete Med 6:112-120
22. Rewers M, Shetterly SM, Baxter J, Marshall JA, Hamman RF 1992 Prevalence of coronary heart disease in subjects with normal and impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a biethnic Colorado population. The San Luis Valley Diabetes Study. Am J Epidemiol 135:1321-1330
23. Eschwège E, Richard JL, Thibult N, Ducimetière P, Warnet JM, Claude JR, Rosselin GE 1985 Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res 15[Suppl]:41-46
24. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H 1983 Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Br Med J 287:867-870
25. Jarrett RJ, Fitzgerald AP 1992 Height and glucose tolerance (letter). Diabetologia 35:191-192
26. Pan WH, Cedres LB, Liu K, Dyer A, Shoenberger JA, Shekelle RB, Stamler R, Smith D, Collette P, Stamler J 1986 Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 123:504-516
27. Perry IJ, Wannamethee SG, Whincup PH, Shaper AG 1994 Asymptomatic hyperglycaemia and major ischaemic heart disease events in Britain. J Epidemiol Community Health 48:538-542
28. Wilson PW, Cupples LA, Kannel WB 1991 Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J 121:586-590
29. Butler WJ, Ostrander Jr LD, Carman WJ, Lamphiear DE 1985 Mortality from coronary heart disease in the Tecumseh Study. Long-term effect of diabetes mellitus, glucose tolerance and other risk factors. Am J Epidemiol 121:541-547
30. Pyörälä K 1979 Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 2:131-141
31. Fujishima M, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Yoshitake T 1996 Diabetes and cardiovascular disease in a prospective population survey in Japan: the Hisayama Study. Diabetes 45[Suppl 3]:S14-S16
32. Donahue RP, Abbott RD, Reed DM, Yano K 1987 Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 36:689-692
33. Wingard DL, Barrett-Connor EL, Scheidt-Nave C, McPhillips JB 1993 Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study. Diabetes Care 16:1022-1025
34. Coutinho M, Wang Y, Gerstein HC, Yusuf S 1996 Continuous relationship of glucose with cardiovascular events in non-diabetic subjects: a meta regression analysis of 18 studies in 88,000 individuals (American Heart Association 69th Meeting). Circulation 94:1-214 (Abstract)
35. Gerstein HC, Yusuf S 1996 Dysglycaemia and risk of cardiovascular disease. Lancet 347:949-950
36. Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, Eschwege E 1998 High blood glucose concentration is a risk factor for mortality in middle-aged non-diabetic men. 20 year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21:360-367
37. Yudkin JS, Forrest RD, Jackson CA 1991 Misclassification of diabetic subjects may account for the increased vascular risk of impaired glucose tolerance: the Islington Diabetes Survey. Diabetes Res Clin Pract 13:1-13
38. Yamasaki Y, Kawamori R, Matsushima H, Nishizawa H, Kodama M, Kubota M, Kajimoto Y, Kamada T 1995 Asymptomatic hyperglycaemia is associated with increased intimal plus medial thickness of the carotid artery. Diabetologia 38:585-591
39. Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M 1996 Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke 27:1986-1992
40. Folsom AR, Eckfeldt JH, Weitzman S, Ma J, Chambless LE, Barnes RW, Cram KB, Hutchinson RG 1994 Relation of carotid artery wall thickness to diabetes mellitus, fasting glucose and insulin, body size, and physical activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke 25:66-73
41. DeRubertis FR, Craven PA 1994 Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 43:1-8
42. Lee TS, Saltsman KA, Ohashi H, King GL 1989 Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci USA 86:5141-5145 (Erratum published in Proc Natl Acad Sci USA 1991;88:9907)
43. Haller H, Baur E, Quass P, Behrend M, Lindschau C, Distler A, Luft FC 1995 High glucose concentrations and protein kinase C isoforms in vascular smooth muscle cells. Kidney Int 47:1057-1067
44. Studer RK, Craven PA, DeRubertis FR 1993 Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes 42:118-126
45. Mene P, Pugliese G, Pricci F, Di Mario U, Cinotti GA, Pugliese F 1993 High glucose inhibits cytosolic calcium signaling in cultured rat mesangial cells. Kidney Int 43:585-591
46. Williams B 1995 Glucose-induced vascular smooth muscle dysfunction: the role of protein kinase C. J Hypertens 13:477-486
47. Williams B, Schrier RW 1992 Characterization of glucose-induced in situ protein kinase C activity in cultured vascular smooth muscle cells. Diabetes 41:1464-1472
48. Brownlee M, Cerami A, Vlassara H 1988 Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321
49. Morrison AD, Orci L, Perrelet A, Winegrad AI 1979 Studies of the effects of an elevated glucose concentration on the ultrastructure and composite metabolism of the intact rabbit aortic intima-media preparation. Diabetes 28:720-723
50. Winegrad AI 1987 Banting Lecture 1986. Does a common mechanism induce the diverse complications of diabetes? Diabetes 36: 396-406
51. Cagliero E, Maiello M, Boeri D, Roy S, Lorenzi M 1988 Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest 82:735-738
52. Gilcrease MZ, Hoover RL 1991 Examination of monocyte adherence to endothelium under hyperglycemic conditions. Am J Pathol 139:1089-1097
53. Haller H, Ziegler W, Lindschau C, Luft FC 1996 Endothelial cell tyrosine kinase receptor and G protein-coupled receptor activation involves distinct protein kinase C isoforms. Arterioscler Thromb Vasc Biol 16:678-686
54. Wolff SP, Dean RT 1987 Glucose autoxidation and protein modification. The potential role of "autoxidative glycosylation" in diabetes. Biochem J 245:243-250
55. Mullarkey CJ, Edelstein D, Brownlee M 1990 Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173:932-939
56. Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T, Nyengaard JR, van den Enden M, Kilo C, Tilton RG 1993 Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801-813
57. Bucala R, Tracey KJ, Cerami A 1991 Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 87: 432-438
58. Brownlee M 1994 Lilly Lecture 1993. Glycation and diabetic complications. Diabetes 43:836-841
59. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A 1988 Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240:1546-1548
60. Lyons TJ 1993 Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 71:26B-31B
61. Lyons TJ 1992 Lipoprotein glycation and its metabolic consequences. Diabetes 41[Suppl 2]:67-73
62. Vlassara H, Bucala R, Striker L 1994 Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70:138-151
63. Haffner SM, Mykkänen L, Valdez R, Stern MP, Holloway DL, Monterrosa A, Bowsher RA 1994 Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab 79:1806-1810
64. Katz RJ, Ratner RE, Cohen RM, Eisenhower E, Verme D 1996 Are insulin and proinsulin independent risk markers for premature coronary artery disease? Diabetes 45:736-741
65. Porte D 1990 Banting Lecture 1990. B-cells in type II diabetes mellitus. Diabetes 40:166-180
66. Bavenholm P, Proudler A, Tornvall P, Godsland I, Landou C, de Faire U, Hamsten A 1995 Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation 92:1422-1429
67. Nordt TK, Schneider DJ, Sobel BE 1994 Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease. Circulation 89:321-330
68. Fontbonne A, Charles MA, Thibult N, Richard JL, Claude JR, Warnet JM, Rosselin GE, Eschwège E 1991 Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15 year follow-up. Diabetologia 34:356-361
69. Pyörälä K 1991 Hyperinsulinaemia as predictor of atherosclerotic vascular disease: epidemiological evidence. Diabete Metab 17:87-92
70. Denker PS, Pollock VE 1992 Fasting serum insulin levels in essential hypertension. A meta-analysis. Arch Intern Med 152:1649-1651
71. Juhan-Vague I, Thompson SG, Jespersen J 1993 Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 13:1865-1873
72. Elliott TG, Viberti G 1993 Relationship between insulin resistance and coronary heart disease in diabetes mellitus and the general population: a critical appraisal. Baillieres Clin Endocrinol Metab 7:1079-1103
73. Laws A, Reaven GM 1993 Insulin resistance and risk factors for coronary heart disease. Baillieres Clin Endocrinol Metab 7:1063-1078
74. De Fronzo R, Ferrannini E 1991 Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194
75. Stout RW 1990 Insulin and atheroma. 20 yr perspective. Diabetes Care 13:631-654
76. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL 1991 Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 87:2246-2252
77. McGill Jr HC, Holman RL 1949 The influence of alloxan diabetes on cholesterol atheromatosis in the rabbit. Proc Soc Exp Biol Med 72:72-73
78. Lehner ND, Clarkson TB, Lofland HB 1971 The effect of insulin deficiency, hypothyroidism, and hypertension on atherosclerosis in the squirrel monkey. Exp Mol Pathol 15:230-244
79. Cruz Jr AB, Amatuzio DS, Grande F, Hay LJ 1961 Effect of intraarterial insulin on tissue cholesterol and fatty acids in alloxandiabetic dogs. Circ Res 9:39-43
80. Stout RW, Bierman EL, Ross R 1975 Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circ Res 36:319-327
81. Pfeifle B, Ditschuneit H 1981 Effect of insulin on growth of cultured human arterial smooth muscle cells. Diabetologia 20:155-158
82. Young IR, Stout RW 1987 Effects of insulin and glucose on the cells of the arterial wall: interaction of insulin with dibutyryl cyclic AMP and low density lipoprotein in arterial cells. Diabete Metab 13: 301-306
83. Oppenheimer MJ, Sundquist K, Bierman EL 1989 Downregulation of high-density lipoprotein receptor in human fibroblasts by insulin and IGF-I. Diabetes 38:117-122
84. Krone W, Greten H 1984 Evidence for post-transcriptional regulation by insulin of 3-hydroxy-3-methylglutaryl coenzyme A reductase and sterol synthesis in human mononuclear leucocytes. Diabetologia 26:366-369
85. Krone W, Naegele H, Behnke B, Greten H 1988 Opposite effects of insulin and catecholamines on LDL-receptor activity in human mononuclear leukocytes. Diabetes 37:1386-1391
86. Wingard DL, Barrett-Connor EL, Ferrara A 1995 Is insulin really a heart disease risk factor? Diabetes Care 18:1299-1304
87. Leonetti F, lozzo P, Giaccari A, Sbraccia P, Buongiorno A, Tamburrano G, Andreani D 1993 Absence of clinically overt atherosclerotic vascular disease and adverse changes in cardiovascular risk factors in 70 patients with insulinoma. J Endocrinol Invest 16:875-880
88. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM 1998 Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 97:996-1001
89. Diabetes Control and Complications Trial Research Group 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
90. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M 1995 Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117
91. Genuth S 1996 Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus. Ann Intern Med 124:104-109
92. Colwell JA 1996 The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. Ann Intern Med 124:131-135
93. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP, Emanuele NV, Levin SR, Pacold I, Lee HS 1997 Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 157:181-188
94. UK Prospective Study Group 1995 UK Prospective Diabetes Study 16: Overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes 44:1249-1258 (Erratum published in Diabetes 1996;45:1655)
95. Nelson RG, Sievers ML, Knowler WC, Swinburn BA, Pettitt DJ, Saad MF, Liebow IM, Howard BV, Bennett PH 1990 Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 81:987-995
96. Ravanam A, Jeffery J, Nehlawi M, Abraira C 1991 Improvement of glucose-primed intravenous glucose tolerance and correction of acute insulin decrement by glipizide in type II diabetes. Metabolism 40:1173-1177
97. Harrower AD 1985 Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opin 9:676-680
98. Kilo C, Dudley J, Kalb E 1991 Evaluation of the efficacy and safety of Diamicron in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract 14[Suppl 2]:S79-S82
99. University Group Diabetes Program 1970 A study of the effect of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. I. Design methods and baseline results. Diabetes 19[Suppl 2]:747-783
100. Grant PJ 1995 The effects of metformin on cardiovascular risk factors. Diabetes Metab Rev 11[Suppl 1]:S43-S50
101. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, D'Onofrio F 1993 Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 44:107-112
102. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F 1993 Metformin inproves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16:1387-1390
103. Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J 1987 Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 57:326-328
104. Montanari G, Bondioli A, Rizzato G, Puttini M, Tremoli E, Mussoni L, Mannucci L, Pazzucconi F, Sirtori CR 1992 Treatment with low dose metformin in patients with peripheral vascular disease. Pharmacol Res 25:63-73
105. Grant PJ 1996 The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 19:64-66
106. Meinert CL, Knatterud GL, Prout TE, Klimt CR 1970 A study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design methods and baseline characteristics. II. Mortality results. Diabetes 19[Suppl 2]:747-830
107. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM 1994 The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 121:928-935
108. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TM 1996 The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 19:1190-1193
109. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fücker K 1991 Therapeutic potentials of acarbose as first line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14:732-737